SMS Pharma's board approved Q1 results: Revenue 206.96 Cr, Consolidated Net Profit 20.90 Cr.

SMS Pharmaceuticals LimitedSMSPHARMA · Filed with the exchange

The MD was re-appointed.

They also approved a Rs 50 Cr loan to subsidiary SMS Peptides, pending shareholder nod, and an AGM for dividend eligibility.

No comments yet. Be the first.

More from SMS Pharmaceuticals Limited

Free

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

No card needed. Takes about a minute.